In contrast, an increased risk of malignancy was suggested in those children who received GH therapy and had underlying conditions that are associated with an increased predisposition to cancer, including RASopathies such as Noonan syndrome, chromosomal breakage syndromes or DNA-repair disorders, such as Fanconi’s anemia and Bloom syndrome [30, 31]. Here, GH1 is linked to cancer.